Abstract
In previous studies we have observed that, in comparison with wild type mice, Tg-CYP2D6 mice have increased serum levels of bufotenine [5-hydroxy-N,N-dimethyltryptamine] following the administration of 5-MeO-DMT. Furthermore, following the injection of 5-MeO-DMT, harmaline was observed to increase serum levels of bufotenine and 5-MeO-DMT in both wild-type and Tg-CYP2D6 mice. In the present investigation, 5-MeO-DMT-induced stimulus control was established in wild-type and Tg-CYP2D6 mice. The two groups did not differ in their rate of acquisition of stimulus control. When tested with bufotenine, no 5-MeO-DMT-appropriate responding was observed. In contrast, the more lipid soluble analog of bufotenine, acetylbufotenine, was followed by an intermediate level of responding. The combination of harmaline with 5-MeO-DMT yielded a statistically significant increase in 5-MeO-DMT-appropriate responding in Tg-CYP2D6 mice; a comparable increase occurred in wild-type mice. In addition, it was noted that harmaline alone was followed by a significant degree of 5-MeO-DMT-appropriate responding in Tg-CYP2D6 mice. It is concluded that wild-type and Tg-CYPD2D6 mice do not differ in terms of acquisition of stimulus control by 5-MeO-DMT or in their response to bufotenine and acetylbufotenine. In both groups of mice, harmaline was found to enhance the stimulus effects of 5-MeO-DMT.
Original language | English (US) |
---|---|
Pages (from-to) | 311-315 |
Number of pages | 5 |
Journal | Pharmacology Biochemistry and Behavior |
Volume | 99 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2011 |
Externally published | Yes |
Keywords
- 5-methoxy-N,N-dimethyltryptamine
- CYP2D6
- Drug interaction
- Drug-induced stimulus control
- Harmaline
- Humanized mice
ASJC Scopus subject areas
- Biochemistry
- Clinical Biochemistry
- Pharmacology
- Toxicology
- Behavioral Neuroscience
- Biological Psychiatry